Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase Not Applicable
Enrollment 864
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for early-stage breast cancer patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Questionnaires — The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16). EORTC QLQ-C30, EORTC QLQ-BR42 and HADS questionnaires are currently used in clinical practice

Primary Outcomes

  • Financial Toxicity at one year (baseline visit (before surgery or chemotherapy/endocrine therapy depending on the cohort), at the end of chemotherapy/endocrine therapy (if applicable), after surgery, 6 months after surgery, 1 year after the baseline questionnaires)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-30
Completion: 2034-09
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 864 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute, Naples
Principal Investigators:
  • Maria Carmela Piccirillo, MD (PRINCIPAL_INVESTIGATOR) - National Cancer Institute, Naples
  • Martina Pagliuca, MD (PRINCIPAL_INVESTIGATOR) - Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples
Contact Information
Study Contact:
Maria Lucia Iacovino, MD
+3908117770692
marialucia.iacovino@istitutotumori.na.it
Maria Carmela Piccirillo, MD
+39 081-1777 0280
m.piccirillo@istitutotumori.na.it
National Cancer Institute of Napoli
Interventions
  • Other: Questionnaires — The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16). EORTC QLQ-C30, EORTC QLQ-BR42 and HADS questionnaires are currently used in clinical practice
Study Locations (1 sites)
National Cancer Institute of Napoli, Naples, Italy
Eligibility Criteria
Inclusion Criteria: * Signed informed consent form * Age \> 18 years at the time of study entry * Histologically confirmed stage I-III invasive breast carcinoma before starting any systemic treatment. Exclusion Criteria: * Stage IV invasive breast carcinoma * Major cognitive dysfunction or psychiatric disorders * Any previous systemic treatment for the current breast cancer
Conditions Breast Cancer Females
Phase NA
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial (prospective case series) is to evaluate the feasibility, safety, and preliminary clinical outcomes of ultrasound-guided dextrose prolotherapy in female breast cancer survivors with persistent ipsilateral chest wall and axillary pain and tightness who have plateaued with standard physical therapy. The main questions it aims to answer are: Does ultrasound-guided dextrose prolotherapy significantly improve upper extremity functional limitation (measured by the QuickDASH questionnaire)? What are the effects of this intervention on pain intensity (NRS), active shoulder range of motion (AROM), and anterior chest wall soft-tissue tightness (pectoralis minor muscle length)? Participants will: Undergo a comprehensive baseline physical examination and ultrasound assessment of the symptomatic chest wall and axilla. Receive three sessions of ultrasound-guided 5% dextrose injections into targeted soft-tissue planes at 4-week intervals. Continue their designated standard rehabilitation program, including range-of-motion and stretching exercises. Attend follow-up assessments at 4-week intervals during the treatment phase, with long-term follow-up at 3 and 6 months after the final injection to evaluate the durability of the response.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: ultrasound guided dextrose prolotherapy — Participants receive three sessions of ultrasound-guided 5% dextrose injections into symptomatic myofascial and interfascial planes of the ipsilateral chest wall and axillary region. The technique involves identifying areas of soft-tissue thickening or restricted fascial glide under high-frequency ultrasound. Injection targets are individualized to each patient's specific site of restriction (e.g., clavipectoral fascia, pectoralis major-minor interface, or axillary fascia). Sessions are administered at 4-week intervals (at weeks 0, 4, and 8).

Primary Outcomes

  • Upper Extremity Function (Baseline, 4 weeks after the 1st injection, 4 weeks after the 2nd injection, 4 weeks after the 3rd injection (approx. 12 weeks from baseline), 3 months after the 3rd injection and 6 months after the 3rd injection)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-11
Completion: 2026-06-28
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taichung Veterans General Hospital
Principal Investigators:
  • Yuchun Lee, M.D. (PRINCIPAL_INVESTIGATOR) - Taichung Veterans General Hospital
Contact Information
Study Contact:
Yuchun Lee, M.D.
886423592525
lyczoj@vghtc.gov.tw
Yuchun Lee, M.D.
886423592525
lyczoj@vghtc.gov.tw
Taichung Veterans Genetal Hospital
Interventions
  • Procedure: ultrasound guided dextrose prolotherapy — Participants receive three sessions of ultrasound-guided 5% dextrose injections into symptomatic myofascial and interfascial planes of the ipsilateral chest wall and axillary region. The technique involves identifying areas of soft-tissue thickening or restricted fascial glide under high-frequency ultrasound. Injection targets are individualized to each patient's specific site of restriction (e.g., clavipectoral fascia, pectoralis major-minor interface, or axillary fascia). Sessions are administered at 4-week intervals (at weeks 0, 4, and 8).
Study Locations (1 sites)
Taichung Veterans Genetal Hospital, Taichung, Taiwan 407 Taiwan
Eligibility Criteria
Inclusion Criteria: * History of breast cancer surgery (mastectomy or breast-conserving surgery), with or without axillary lymph node dissection * Persistent ipsilateral chest wall and/or axillary pain, tightness, or movement restriction lasting ≥ 3 months after surgery; * Clinically significant baseline symptom severity, defined as Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire ≥ 25 and/or pain intensity ≥ 5/10 on the Numeric Rating Scale (NRS); * Completion of 12 weeks of standard physical therapy with no significant improvement, defined as a change in QuickDASH score from baseline to completion of therapy below the minimal clinically important difference (MCID; \<15 points ) and/or pain improvement \< 2 points on the NRS . * Age ≥ 18 years; * Ability to provide written informed consent. Exclusion Criteria: * Evidence of local cancer recurrence or metastatic disease; * Active lymphedema requiring ongoing decongestive therapy at the time of enrollment; * Shoulder pathology, including intra-articular or peri-articular conditions (e.g., adhesive capsulitis with marked capsular restriction, or acute rotator cuff tear,) judged by clinical assessment to be the dominant cause of symptoms. * Active infection, skin lesion, or unhealed surgical wound at the intended injection site; * Known bleeding disorders or anticoagulant use contraindicating injection; * Known allergy to dextrose or any components of the injection protocol; * Pregnancy or other medical conditions precluding participation.
Conditions Hereditary Pancreatic Cancer, Conditions...
Phase NA
Enrollment 1000
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite of implementation strategies to increase germline test ordering by oncology care teams (i.e., mainstreaming) for eligible patients with breast, pancreatic or colorectal cancer. Secondarily, the study will investigate completion of testing by eligible patients, as well as impact on overall rates of germline test ordering in patients with cancer. The network will bundle and deploy different implementation strategies across the clinical sites in three 6-month phases. A maintenance phase after the implementation periods will measure genetic testing rates without any additional implementation strategies to determine persistence of effects. The implementation strategies address clinician-level factors, and thus oncologists and their team members (e.g. advanced practice providers, nurse navigators, case managers) will be the focus of evaluating the impact of implementation strategies. Strategies that will be considered include provider education, audit and feedback reports, facilitation, peer support, and electronic health record (EHR) system optimization to support germline testing. Using the RE-AIM QuEST framework, outcomes will be assessed using mixed methods separately for each eligible cancer type. Data collection from the EHR, other relevant data sources, and qualitative provider feedback will be used to assess ordering and completion of tests and the effect of the implementation strategies on germline testing rates in oncology clinics.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Implementation strategies — We will deploy different strategy bundles across the clinical sites in three approximate 6-month phases. Phase I - Facilitation of provider training, educational materials, and information resources; Patient-facing educational material and information resources Phase II - Audit and feedback report on existing patients; Practice champion support; Optimizing EHR strategies Phase III - EHR tools to facilitate prospective identification of patients, testing, and result reporting

Primary Outcomes

  • Germline Genetic Testing Ordered for Breast Cancer Patients (48 months)
  • Germline Genetic Testing Ordered for Pancreatic Cancer Patients (48 months)
  • Germline Genetic Testing Ordered for Colorectal Cancer Patients (48 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-30
Completion: 2030-01-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Josh Peterson
Collaborators: National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)
Principal Investigators:
  • Josh F Peterson, MD, MPH (PRINCIPAL_INVESTIGATOR) - Vanderbilt University Medical Center
Contact Information
Study Contact:
Megan He, PhD
615-875-9641
megan.he@vumc.org
Lynn A Seabolt, MS, RD
615-875-7898
lynn.a.seabolt@vumc.org
Abby Sokoloff
abby.sokoloff@va.gov
VA Greater Los Angeles Healthcare System
Interventions
  • Behavioral: Implementation strategies — We will deploy different strategy bundles across the clinical sites in three approximate 6-month phases. Phase I - Facilitation of provider training, educational materials, and information resources; Patient-facing educational material and information resources Phase II - Audit and feedback report on existing patients; Practice champion support; Optimizing EHR strategies Phase III - EHR tools to facilitate prospective identification of patients, testing, and result reporting
Study Locations (10 sites)
VA Greater Los Angeles Healthcare System, Los Angeles, California 90073 United States
Orlando VA Medical Center, Orlando, Florida 32827 United States
Atlanta VA Medical Center, Decatur, Georgia 30033 United States
Northwestern Medicine, Chicago, Illinois 60611 United States
Indiana University School of Medicine, Indianapolis, Indiana 46202 United States
Durham VA Medical Center, Durham, North Carolina 27705 United States
Salisbury VA Health Care System, Salisbury, North Carolina 28144 United States
Geisinger, Danville, Pennsylvania 17822 United States
Vanderbilt University Medical Center, Nashville, Tennessee 37203 United States
University of Utah Health, Salt Lake City, Utah 84112 United States
Eligibility Criteria
Inclusion Criteria: * Oncology care team members (including, but not limited to, oncologists, advanced practice providers, nurse navigators, caring for patients with adult patients with breast cancer, pancreatic cancer or colorectal cancer. Exclusion Criteria: * Providers not on the oncology care team
Conditions Serious Mental Illness, Psychotic Disord...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Changing Lives and Changing Outcomes-9 — A brief, cognitive therapy-based intervention for people with mental illness and legal system involvement.

Primary Outcomes

  • Buss-Perry Aggression Questionnaire (From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment))
  • Modified Colorado Symptom Index (From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment))
  • Psychological Inventory of Criminal Thinking Styles-Short Form (From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment))
  • Measure of Criminal Attitudes and Associates (From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment))
  • CLCO-9 knowledge quiz (From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-05
Completion: 2027-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Worcester Recovery Center and Hospital
Principal Investigators:
  • Faith Scanlon, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Faith Scanlon, PhD
6177242079
fscanlon@mgh.harvard.edu
Corinne Cather, PhD
6177266692
CCATHER@mgh.harvard.edu
Faith Scanlon, PhD
6177242079
fscanlon@mgh.harvard.edu
Worcester Recovery Center and Hospital
Interventions
  • Behavioral: Changing Lives and Changing Outcomes-9 — A brief, cognitive therapy-based intervention for people with mental illness and legal system involvement.
Study Locations (1 sites)
Worcester Recovery Center and Hospital, Worcester, Massachusetts 02451 United States
Eligibility Criteria
Inclusion Criteria: * Currently hospitalized at Worcester Recovery Center and Hospital (WRCH) * At least 18 years old * Self-reported current or past legal involvement * Speaks English * For patients without a legally authorized representative (LAR): demonstrate capacity to consent per the Capacity Assessment Record (CAR). * For patients with an LAR: assent to participate. Exclusion Criteria: * Hospital status that does not permit group attendance (e.g., room-based seclusion)
Conditions Airway Assessment
Phase Not Applicable
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Clinical and ultrasound indices of airway, in addition to laryngoscopic view will be assessed and compared among three groups of patients: non pregnant, pregnant with normal blood pressure, preeclampsia patients undergoing various surgeries under general anesthesia.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Sperficial ultrasonographic airway assessemt (preoperative just before induction of anesthesia)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-15
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: South Valley University
Contact Information
Study Contact:
Zeinab M Sayed, MD
01009071365
zeinab5aton@gmail.com
ZAINAB MOSTAFA
01009071365
zeinab5aton@gmail.com
Qena University
Interventions
N/A
Study Locations (1 sites)
Qena University, Qina, Qena Governorate 83511 Egypt
Eligibility Criteria
Inclusion Criteria: * -normotensive pregnant * pre-eclamptic patients. * nonpregnant females in child bearing period . Exclusion Criteria: * Patients excluded were women at \<32 weeks' gestation or with Eclampsia . * height \<150 cm, body mass index (BMI) \>30 kg/m2 . * predicted airwy difficulty due to any other cause as neck swelling , facial deformity and prominent teeth.
Conditions ADHD, Depression Disorders, Mood Disorde...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Interventions / Regimen

  • Drug: Prescription Psychotropic Medications — Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.

Primary Outcomes

  • Collection of Ophthalmic Data (1 Day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-17
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gaize
Contact Information
Study Contact:
Apurva Raje Research Coordinator / Principal Investigator, BA
732-397-1795
apurva.raje@gaize.ai
Rob Kaufmann CTO
rob.kaufmann@gaize.ai
Apurva Raje Research Coordinator / Principal Investigator
732-397-1795
apurva.raje@gaize.ai
Gaize
Interventions
  • Drug: Prescription Psychotropic Medications — Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.
Study Locations (1 sites)
Gaize, Philadelphia, Pennsylvania 19130 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged between 18 and 65, having given written informed consent to participate in the research trial. * Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months. * Normal or corrected to normal vision using either glasses or contact lenses, or surgery. Exclusion Criteria: * Enrolled in, or participated in another clinical trial within 30 days before the study * Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days. * Had your eyes dilated by a medical doctor in the previous 24 hours. * Photosensitive epilepsy * Diagnosed with clinical blindness * Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded. * Current or past head inject/ traumatic brain injury (TBI) * Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications. * History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well. * Potential participants who are unable to provide consent for the study.
Conditions Parkinson Disease
Phase NA
Enrollment 42
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremors, and postural instability, as well as various non-motor symptoms. Conventional land-based rehabilitation is standard; however, aquatherapy-utilizing water's buoyancy, hydrostatic pressure, and viscosity-offers a promising alternative to improve balance and mobility while reducing fall risks. This study aims to evaluate the effects of aquatherapy on gait, balance, posture, freezing of gait, activities of daily living (ADL), pain, and depression in Turkish PD patients. This is a prospective, single-blind, randomized controlled trial involving 42 patients at Ankara City Hospital. Participants will be divided into two groups: * Group 1 (Control): Home-based exercise program (5 days/week for 6 weeks). * Group 2 (Intervention): Home-based exercises plus supervised aquatherapy (3 sessions/week, 45 minutes each, in a 30-32°C pool). The study utilizes high-tech objective measurements and validated scales: * Gait \& Posture: Zebris Gait Analysis (spatiotemporal parameters) and Diers Formetric 4D (topographical posture analysis). * Balance: HUR-Smart Balance device and the Berg Balance Scale. * Clinical Scales: PDQ-39 (quality of life), Freezing of Gait Questionnaire, Falls Efficacy Scale, MMSE (cognitive), Beck Depression Inventory, and VAS (pain). This research is noteworthy as the first aquatherapy study among Turkish PD patients to utilize a large sample size and standardized aquatic exercise protocols. It seeks to provide a comprehensive analysis of both motor and non-motor improvements, potentially establishing aquatherapy as a superior adjunctive treatment for enhancing functional independence in Parkinson's patients. Primary hypothesis or outcome measure : Parkinson's Disease Questionnaire-39 . PDQ-39 is a patient-reported outcome measure designed to evaluate the health-related quality of life in Parkinson's patients across eight specific domains, including mobility, activities of daily living, and emotional well-being.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Aquatherapy — The specific aquatic exercise protocol for Group 2, conducted in a 120 cm deep therapy pool at 30-32°C, includes the following exercises: Gait and Mobility: Water walking (forward and backward) and side-stepping. Dynamic Balance: Forward and lateral lunges, and single-leg stance/balance drills. Lower Extremity Strengthening: Hip kicks performed at the pool wall (flexion, extension, and abduction) and standing knee raises. Upper Body and Coordination: Arm raises (multi-directional) and deep-water cycling movements. Home Exercise Component: In addition to aquatic sessions, patients will continue land-based exercises including posture correction, flexibility/stretching, balance-coordination training, and strengthening.
  • Other: home exercise — Group 1 patients will be prescribed a home exercise program at least 5 days per week for a duration of 6 weeks

Primary Outcomes

  • Parkinson's Disease Questionnaire-39 (From enrollment to the end of treatment at 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-08-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ankara City Hospital Bilkent
Principal Investigators:
  • Halil Uçan, Prof. Doctor (STUDY_DIRECTOR) - Bilkent City Hospital
Contact Information
Study Contact:
Duygu Yanıktaş, MD
+905059025460
yanktasduygu@gmail.com
Duygu Yanıktaş, MD
05059025460
yanktasduygu@gmail.com
Bilkent City Hospital
Duygu Yanıktaş, MD
Bilkent City Hospital
Interventions
  • Other: Aquatherapy — The specific aquatic exercise protocol for Group 2, conducted in a 120 cm deep therapy pool at 30-32°C, includes the following exercises: Gait and Mobility: Water walking (forward and backward) and side-stepping. Dynamic Balance: Forward and lateral lunges, and single-leg stance/balance drills. Lower Extremity Strengthening: Hip kicks performed at the pool wall (flexion, extension, and abduction) and standing knee raises. Upper Body and Coordination: Arm raises (multi-directional) and deep-water cycling movements. Home Exercise Component: In addition to aquatic sessions, patients will continue land-based exercises including posture correction, flexibility/stretching, balance-coordination training, and strengthening.
  • Other: home exercise — Group 1 patients will be prescribed a home exercise program at least 5 days per week for a duration of 6 weeks
Study Locations (2 sites)
Bilkent City Hospital, Çankaya, Ankara 06800 Turkey (Türkiye)
Bilkent City Hospital, Ankara, ÇANKAYA 06800 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Having a diagnosis of Idiopathic Parkinson's Disease between the ages of 40-80 and consenting to the treatment. * Being regularly followed by a neurologist and having a stable medical treatment regimen for at least 3 months. * Having a disease stage between 1-3 according to the Modified Hoehn-Yahr Staging Scale (MHY). * A score of 24 or higher on the Mini-Mental State Examination (MMSE). * Being able to verticalize independently and ambulate with or without assistance. Exclusion Criteria: * Having orthopedic, rheumatological, or non-Parkinson's neurological disorders that affect functional status. * Having a medical treatment regimen that has been modified within the last 3 months. * Presence of Atypical Parkinson's Disease. * Visual impairment. * Presence of dementia. * Decompensated cardiac or respiratory failure. * Diabetes insipidus. * Presence of systemic infection. * Impaired skin integrity or the presence of skin infections. * Increased sensitivity to inhaled steam or water chemicals. * History of epilepsy or asthma. * Urinary or fecal incontinence. * Refusal to participate in or consent to the treatment.
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase NA
Enrollment 160
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period. A total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: RT-CGM — RT-CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.
  • Device: SMBG — SMBG provides discrete, point-in-time capillary blood glucose measurements via fingerstick testing.

Primary Outcomes

  • Difference between change in HbA1c between the intervention group and the control group at Week 12 (from baseline to Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-11
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai 6th People's Hospital
Collaborators: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Fengxian District Central Hospital, Shanghai 7th People's Hospital
Principal Investigators:
  • Jian Zhou (PRINCIPAL_INVESTIGATOR) - Shanghai 6th People's Hospital
Contact Information
Study Contact:
Jian Zhou
86-21-64369181
zhoujian@sjtu.edu.cn
Xiaohua Li
021-58670561
13816805177@163.com
Shanghai 7th People's Hospital
Jian Zhou
86-21-64369181
zhoujian@sjtu.edu.cn
Shanghai 6th People's Hospital
Interventions
  • Device: RT-CGM — RT-CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.
  • Device: SMBG — SMBG provides discrete, point-in-time capillary blood glucose measurements via fingerstick testing.
Study Locations (4 sites)
Shanghai 7th People's Hospital, Shanghai, 200137 China
Shanghai 6th People's Hospital, Shanghai, China
Shanghai Fengxian District Central Hospital, Shanghai, China
Shanghai General Hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Age 18 to 80 years (inclusive). 2. Confirmed diagnosis of type 2 diabetes mellitus (T2DM). 3. HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening/enrollment. 4. Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed/confirmed by the treating physician (principal physician). Exclusion Criteria: 1. Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment. 2. Severe skin disease at the sensor insertion site, or allergy to adhesive tape/adhesives. 3. Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period. 4. Currently participating in, or planning to participate in, another clinical trial. 5. Current use of oral corticosteroid therapy, or anticipated use during the trial period. 6. Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times the upper limit of normal (ULN). 7. Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m². 8. Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand/comply due to speech/language impairment; or presence of psychiatric disorders.
Conditions Anxiety, Anxiety Depression
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Brief Summary of the Study The aim of this clinical trial is to find out if the group therapy method "Self-Reconstruction" helps to reduce anxiety in adults. The researchers want to see if the participants' emotional state becomes more stable after completing the course. The main questions that this study aims to answer are: Do people's anxiety levels decrease after taking the course of "I-Reconstruction" classes? Do the positive effects of the classes persist 3, 6 and 12 months after they finish? Do the participants' quality of life and ability to enjoy life improve? The researchers will compare a group of people who attend the therapy classes with a group of people who receive usual care to see if the new method is more effective. Participants will: Participate in 10 online group meetings once a week. Do simple breathing and movement exercises to calm the body and emotions. Discuss your feelings and desires with a professional in a safe group. Complete questionnaires about your condition at the beginning, during, and after the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Experimental: Active "I-Reconstruction" Therapy — The intervention consisted of a structured group psychotherapy program based on the "l-Reconstruction" method. The program included ten weekly group sessions, each lasting 120 minutes, delivered online by a certified therapist trained in the method. The intervention targeted anxiety through therapeutic work with preverbal trauma and internal conflicts by reconstructing core personality components related to desire, ownership, and the capacity for pleasure. The therapeutic process combined psychoeducation, analysis of preverbal acts, exploration of emotional and bodily responses, reconstruction of traumatic experiential patterns, and structured group reflection and integration. The intervention followed a standardized protocol to ensure consistency across groups and therapists.
  • Drug: Standard Care (Treatment as Usual) — Participants assigned to the control group did not receive any structured psychotherapeutic intervention as part of the study. During the intervention period, no active treatment, group sessions, or therapeutic procedures were provided by the research team. The control condition was designed to serve as a non-intervention comparison group for evaluating the effects of the "l-Reconstruction" group psychotherapy.

Primary Outcomes

  • Change in anxiety level on the Beck Anxiety Inventory (BAI) from baseline to 12 months after therapy (T1: Baseline (before the intervention); T2: 5 weeks (mid-intervention); T3: 10 weeks (immediately after the intervention); T4: 22 weeks (3 months after the intervention); T5: 34 weeks (6 months after the intervention); T6: 60 weeks (12 months after))
  • Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) subscale scores from baseline to 12 months after therapy (T1: Baseline (before the intervention); T2: 5 weeks (mid-intervention); T3: 10 weeks (immediately after the intervention); T4: 22 weeks (3 months after the intervention); T5: 34 weeks (6 months after the intervention); T6: 60 weeks (12 months after))
  • Change in total score according to the "I - Reconstruction" diagnosis of preverbal dysregulation (DPD) method from baseline to 12 months after therapy (T1: Baseline (before the intervention); T2: 5 weeks (mid-intervention); T3: 10 weeks (immediately after the intervention); T4: 22 weeks (3 months after the intervention); T5: 34 weeks (6 months after the intervention); T6: 60 weeks (12 months after))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-02
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: International Association Psychosomatics And Health Therapy
Principal Investigators:
  • Tetiana Pavlenko (PRINCIPAL_INVESTIGATOR) - International Association of Psychosomatics and Health Therapy
Contact Information
Study Contact:
Tetiana Pavlenko
+380976953203
tanjapavlenko28223@gmail.com
Tetiana Pavlenko
+380976953203
tanjapavlenko28223@gmail.com
International Association of Psychosomatics and Body Therapy
Interventions
  • Drug: Experimental: Active "I-Reconstruction" Therapy — The intervention consisted of a structured group psychotherapy program based on the "l-Reconstruction" method. The program included ten weekly group sessions, each lasting 120 minutes, delivered online by a certified therapist trained in the method. The intervention targeted anxiety through therapeutic work with preverbal trauma and internal conflicts by reconstructing core personality components related to desire, ownership, and the capacity for pleasure. The therapeutic process combined psychoeducation, analysis of preverbal acts, exploration of emotional and bodily responses, reconstruction of traumatic experiential patterns, and structured group reflection and integration. The intervention followed a standardized protocol to ensure consistency across groups and therapists.
  • Drug: Standard Care (Treatment as Usual) — Participants assigned to the control group did not receive any structured psychotherapeutic intervention as part of the study. During the intervention period, no active treatment, group sessions, or therapeutic procedures were provided by the research team. The control condition was designed to serve as a non-intervention comparison group for evaluating the effects of the "l-Reconstruction" group psychotherapy.
Study Locations (1 sites)
International Association of Psychosomatics and Body Therapy, Kyiv, Kyiv Oblast 03057 Ukraine
Eligibility Criteria
Inclusion Criteria: Age between 18 and 55 years (inclusive). Clinically significant level of anxiety according to the Beck Anxiety Inventory (BAI) ≥ 9 points. Anxiety subscale score on the Hospital Anxiety and Depression Scale (HADS-A) ≥ 11 points. Significant level of preverbal trauma according to the "Diagnostics of Preverbal Dysregulation" (DPD, T. Pavlenko) questionnaire: total score ≥ 16. Specific subscale scores in DPD: "Desire" ≥ 5, "Satisfaction" ≥ 5, and "Possession" (Obsession) ≥ 6 points. Presence of internal conflicts according to the "Internal Conflict Test" (ICT) ≥ 1 point on the skin tissue measurement scale. Willingness to comply with the study protocol and the online therapy format. Exclusion Criteria: Current participation in any other psychotherapy during the study. Use of any psychotropic medications within the last 30 days (antidepressants, tranquilizers, neuroleptics, mood stabilizers). Diagnosed severe mental disorders (according to ICD-10/DSM-5) requiring specialized psychiatric care or inpatient treatment. Presence of acute suicidal risk. Substance abuse (alcoholism, drug addiction). Failure to meet any of the threshold values specified in the inclusion criteria.
Conditions Suicide, Mental Health Disorder, Anhedon...
Phase NA
Enrollment 100
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to increase engagement with effective interventions such as suicide safety planning. The BRITE suicide safety planning app was developed on evidence-based principles and has undergone rigorous formative development and effectiveness evaluations. However, to optimize its functionality, commercial viability, and scale its implementation, issues related to user engagement needed to be addressed. This 3 month Pragmatic Randomized Trial will evaluate the impact of the ViraSafe app-an enhanced version of the BRITE suicide safety planning app-on improving engagement with coping skills and safety planning among suicidal adolescents by comparing its intervention components to those of the original BRITE app.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: ViraSafe: Treatment pushes — ViraSafe participants will complete a safety plan with their provider. Safety plan content will be editable and viewable throughout the intervention for both participants and their providers. Participants will be able to access the safety plan at any time in ViraSafe. Additionally, patients using ViraSafe will be prompted to complete a daily distress rating. ViraSafe uses automated algorithms (i.e., just in time adaptive intervention features) and user input from distress ratings to facilitate increased engagement with coping skills and pushes safety planning materials to users at periods of high risk (i.e., increases in emotional distress). In addition to the just-in-time reminders (i.e., nudges) pushed automatically by the system, through the Vira Pro platform, practitioners can schedule just-in-time reminders (i.e., "nudges") to arrive in the user's phone to support their behavior change plan.
  • Behavioral: BRITE — The BRITE app contains the teen's safety plan, links to videos of how to use coping strategies they indicated in their safety plan that have been useful for them (like guided mediation or deep breathing), a library of evidence-based and age-appropriate coping skills and strategies that the adolescent can learn more about, photos or videos that the adolescent has uploaded to the app, and includes a question asking them to rate their distress level in the moment: "What is your distress level right now?" (1 is "Least Distressed" to 5, which is "Most Distressed"). Then, the teen is asked to identify the feeling that fits their distress level via 12 emoji images: "Which feelings fit your distress level?" Based on adolescent's distress rate, the BRITE app suggests coping skills or "activities" for the adolescent to lower their distress level.

Primary Outcomes

  • Proximal Engagement (24 hours)
  • Engagement with the apps (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-18
Completion: 2027-12-31
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ksana Health
Collaborators: National Institute of Mental Health (NIMH), University of Pittsburgh Medical Center
Contact Information
Study Contact:
Stephanie Stepp, PhD
412-383-5051
steppsd@upmc.edu
Nick Allen Co-Founder & CEO, PhD
206-745-9419
nick.allen@ksanahealth.com
Ksana Health Inc
David Brent Co-Director, MD
412-246-5619
Brentda@upmc.edu
STAR Center, Western Psychiatric Institute & Clinic
Interventions
  • Behavioral: ViraSafe: Treatment pushes — ViraSafe participants will complete a safety plan with their provider. Safety plan content will be editable and viewable throughout the intervention for both participants and their providers. Participants will be able to access the safety plan at any time in ViraSafe. Additionally, patients using ViraSafe will be prompted to complete a daily distress rating. ViraSafe uses automated algorithms (i.e., just in time adaptive intervention features) and user input from distress ratings to facilitate increased engagement with coping skills and pushes safety planning materials to users at periods of high risk (i.e., increases in emotional distress). In addition to the just-in-time reminders (i.e., nudges) pushed automatically by the system, through the Vira Pro platform, practitioners can schedule just-in-time reminders (i.e., "nudges") to arrive in the user's phone to support their behavior change plan.
  • Behavioral: BRITE — The BRITE app contains the teen's safety plan, links to videos of how to use coping strategies they indicated in their safety plan that have been useful for them (like guided mediation or deep breathing), a library of evidence-based and age-appropriate coping skills and strategies that the adolescent can learn more about, photos or videos that the adolescent has uploaded to the app, and includes a question asking them to rate their distress level in the moment: "What is your distress level right now?" (1 is "Least Distressed" to 5, which is "Most Distressed"). Then, the teen is asked to identify the feeling that fits their distress level via 12 emoji images: "Which feelings fit your distress level?" Based on adolescent's distress rate, the BRITE app suggests coping skills or "activities" for the adolescent to lower their distress level.
Study Locations (3 sites)
Ksana Health Inc, Eugene, Oregon 97405 United States
STAR Center, Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania 15213 United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: Youth (minors): * 13-17 years old * Suicide attempt in the last year and ideation in the past month * English fluency and literacy * Parent or legal guardian willing and able to legally provide informed consent * Receiving care at one of the study clinical settings with trained providers to onboard ViraSafe or BRITE safety plan Youth (adults) * 18-24 years old * Recent suicide attempt or ideation with a plan * English fluency and literacy * Receiving care at one of the study clinical settings with trained providers to onboard ViraSafe or BRITE safety plan. Exclusion Criteria: Youth (minors): * Unable to read/understand English * Current manic or psychotic episode * Development disability precluding comprehension of study procedures * No routine access to a mobile phone, assessed by EHR review and during phone screen * No eligible parent or legal guardian to provide informed consent Youth (adults): * Unable to read/understand English * Current manic or psychotic episode * Development disability precluding comprehension of study procedures * No routine access to a mobile phone, assessed by EHR review and during phone screen
Conditions Cancer, Solid Tumor Cancer, Advanced Met...
Phase PHASE1
Enrollment 386
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works. Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive SYS6043 by intravenous infusion once every 3 weeks (Q3W), with 21 days as one treatment cycle until the study doctor determines that study treatment should be stopped based on how well a participant is doing on treatment. * Have safety follow-up (SFU), and long-term follow-up. * Be followed until progression.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SYS6043 — Administered by intravenous injection

Primary Outcomes

  • Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a). (An average of 1 year.)
  • Incidence of Treatment-Emergent Adverse Events and dose-limiting toxicities (DLTs) [Safety and Tolerability] of SYS6043 during the study (Phase 1a) (An average 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-03-03
Completion: 2030-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 386 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Conjupro Biotherapeutics, Inc.
Contact Information
Study Contact:
Director, Clinical Operations
609-356-0210
clinicaltrials.gov@cspcus.com
Regulatory Operations Manager
609-356-0210
clinicaltrials.gov@cspcus.com
Dr Sawhney, Principal Investigator
561-447-0614
BRCR Global
Interventions
  • Drug: SYS6043 — Administered by intravenous injection
Study Locations (5 sites)
BRCR Global, Plantation, Florida 33322 United States
Florida Clinical Trials Group, Plantation, Florida 33322 United States
NEXT Oncology Austin, Austin, Texas 78758 United States
NEXT Oncology San Antonio, San Antonio, Texas 78229 United States
NEXT Oncology Virginia, Fairfax, Virginia 22031 United States
Eligibility Criteria
Inclusion Criteria: Major: * Aged ≥18 years old (on the date of signing the ICF). * Advanced/unresectable or metastatic solid tumors confirmed by histology or cytology, disease recurrence or progression during or after systemic standard of care, and should be intolerant of or have no available standard of care therapy. * Have at least one measurable lesion, according to the Response Evaluation Criteria in Solid Tumors (RECIST V1.1). Participants with metastatic castration-resistant prostate cancer (mCRPC) who have only metastases to bone will be evaluated through discussion with the sponsor's medical monitor, before determining whether they can be enrolled. * Expected life expectancy of ≥ 3 months. * ECOG performance status of 0-1 and no worsening of the score within 28 days prior to enrollment. * LVEF ≥ 50% as shown by ECHO or MUGA within 28 days prior to enrollment. Exclusion Criteria: Major: * Prior B7-H3 targeted therapy. * Previously received drug therapy with topoisomerase inhibitor antibody-drug conjugate (e.g., trastuzumab deruxtecan). * Symptomatic congestive heart failure (CHF) (New York Heart Association \[NYHA\] Class II-IV) or a history of severe arrhythmia requiring treatment. * History of myocardial infarction or unstable angina within 6 months prior to enrollment. * Based on the results of three 12-lead electrocardiogram (ECG) examinations, the mean QT interval (QTcF) corrected by the Fridericia formula for both males and females is prolonged to \>470 ms. * Unable or unwilling to discontinue concomitant medications known to prolong the QT interval. * History of interstitial lung disease (e.g., ILD/non-infectious pneumonia requiring glucocorticoid treatment in the past), or currently have interstitial lung disease, or are suspected to have such diseases through imaging examinations during screening. * History of underlying lung disorders, including but not limited to pulmonary embolism within 3 months prior to the start of study treatment, severe asthma, severe COPD, restrictive pulmonary disease, and other clinically significant lung injuries or requiring supplemental oxygen. * Any autoimmune diseases, connective tissue disorders, or inflammatory diseases involving the lungs recorded or suspected during screening (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.). * Presence of uncontrolled infection requiring intravenous injection of antibiotics, antiviral drugs, or antifungal drugs. * Active and clinically significant bacterial, fungal, viral infection, or Hepatitis C infection at screening (HCV antibodies test positive and HCV-RNA levels higher than the lower limit of quantification or 1000 copies/mL (whichever is lower); HIV antibody positive or syphilis antibody positive (with confirmation).. * HBsAg positive and HBV-DNA above the lower limit of quantification or 1,000 copies/mL (500 IU/mL) (whichever is lower). Liver tumor: For participants with liver metastases and HBV infection, HBV DNA must be \<2000 IU/mL before the first dose. Participants who are HBsAg-positive and/or HBV DNA-positive should receive at least 2 weeks of anti-Hepatitis B virus treatment prior to the first dose and be willing to continue treatment during the study. * Lactating women (women who are willing to temporarily discontinue breastfeeding will also be excluded), or women confirmed to be pregnant by pregnancy test within 7 days prior to enrollment. * Presence of spinal cord compression or clinically active brain metastasis, and/or meningeal metastases, defined as untreated, symptomatic, or requiring corticosteroids or anticonvulsants.
Conditions Environmental Exposure, Asthma, Bronchie...
Phase Not Applicable
Enrollment 125
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, observational study of patients aged 18-80 years with clinical diagnosis of bronchial asthma, allergic bronchopulmonary aspergillosis (ABPA), bronchiectasis and healthy subjects. Among them, the bronchial asthma group will be divided into asthma control group, asthma partial control group and asthma uncontrolled group according to the GINA asthma control classification. Record the baseline information of the subjects in detail, including basic information, disease course, smoking, previous acute attacks and hospitalizations, long-term medication, etc. (including the frequency, dose and duration of ICS use, antifungal drug type, dose, duration of use, and course of treatment), and evaluate and record environmental factors (such as indoor).Humidity, temperature, ventilation, pet keeping, plant planting, etc.) and other lifestyle factors that may affect disease control and fungal exposure. The patient's disease status was assessed using questionnaire scores. Sputum samples were taken at the time of enrollment.Set (asthma ABPA group uses sputum induction), pulmonary function test and bronchodilator test, FeNO measurement (asthma ABPA group only), blood routine test, Aspergillus-specific IgE and IgG detection, total immunoglobulin IgE, allergen detection, etc. Dust was collected indoors (bedrooms), outdoor (balconies) and on the surface of air conditioners or fans (if applicable) in the subject's living environment, and environmental data such as ambient temperature, humidity, and particulate matter concentration were recorded. 18S rRNA technology was used for sputum and dust fungus detection, and ELISA was used for asthmatitis symptomatic markers, which assess the impact of fungal infections on the disease. Follow-up for each subject 6 months, 6 months after enrollment, the patient's symptom changes, acute exacerbations/exacerbations, and prognosis were recorded, and relevant questionnaire scores were completed.

Design

Study type: Observational Observational model: Other Time perspective: Other

Primary Outcomes

  • Respiratory fungi (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-23
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 125 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Ningbo University
Contact Information
Study Contact:
Chao Cao
+86-0574-87089878
caocdoctor@163.com
Shiyi He
+86-0574-87089878
shiyihii@163.com
Chao CAO
+86-0574-87089878
caodoctor@163.com
The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Recruiting
Interventions
N/A
Study Locations (1 sites)
The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Recruiting, Ningbo, Zhejiang 315010 China
Eligibility Criteria
Inclusion Criteria: 1. Age range of 18-80 years old (including 18 and 80 years old), gender and race are not limited; 2. No history of asthma, ABPA, or other chronic respiratory diseases. 3. No history of allergic diseases, such as allergic rhinitis, eczema, or food allergies. 4. Pulmonary function is normal or close to the normal range. 5. Laboratory testing: 1\. Blood routine: High sensitivity C-reactive protein, white blood cells, neutrophils, lymphocytes, and monocytes are all within the normal range. Allergen testing: IgE levels for common allergens such as dust mites, cat hair, dog hair, cockroaches, mold, and pollen are normal or close to the normal range. Exclusion Criteria: 1. Suffering from bronchial asthma ABPA、 Bronchiectasis or other respiratory diseases: chronic obstructive pulmonary disease, active pulmonary tuberculosis, pulmonary embolism, lung cancer, pneumothorax, hemoptysis, pulmonary arterial hypertension, interstitial lung disease, etc; 2. Cancer patients who suffer from serious other systemic diseases, such as myocardial infarction, stroke, hypertensive crisis or refractory hypertension, severe arrhythmia, heart failure, aortic aneurysm, liver failure, renal failure, hematological disorders, etc., and have recently been discovered or are currently receiving treatment; 3. Four weeks prior to enrollment, systemic use of antibiotics, antifungal drugs, immunosuppressants, cytotoxic agents, hormones, etc; 4. Other individuals with contraindications for induced sputum testing: